Medical Condition News

RSS

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.

2 Feb 2011

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

An innovative diabetes management concept including structured self-monitoring of blood glucose (SMBG), data visualization, pattern analysis and derived therapy adjustments can significantly reduce HbA1c values, improve glycemic control and enhance patients' quality of life. These are the key findings of the 12-month data from the Structured Testing Protocol (STeP) Study, newly published in Diabetes Care.

2 Feb 2011

New study evaluates ideal crown-to-root ratio for successful implant restoration

Dental implants are now a common way to replace a tooth. But a dentist must first determine that an implant restoration can be successful for a particular patient. As an indicator, dentists use the crown-to-root ratio—how much of the tooth extends above the jawbone and how much is in the bone. However, the ideal crown-to-implant ratio for the replacement tooth has yet to be determined.

2 Feb 2011

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

A new evidence report by ECRI Institute comparing the effectiveness of various treatments for bulimia nervosa indicates that cognitive behavioral therapy is more effective than antidepressant medications and supportive therapies in improving eating disorder symptoms.

2 Feb 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."

2 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Study identifies effects of multiple previous concussions on high school students

A previous study of ex-NFL players showed that the damage caused by concussions occurs in the same region of the brain as damage caused by Alzheimer's disease, resulting in increased concern over post-concussion related injuries and trauma of athletes. Philip Schatz Ph.D., professor of psychology, and his associates recently published a study in Neurosurgery that identifies potentially enduring effects of multiple previous concussions on high school students.

2 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

New national initiative to increase heart attack awareness among women

A woman suffers a heart attack every minute in the United States. But according to a 2009 American Heart Association survey, only half of women said they would call 9-1-1 if they thought they were having a heart attack -- and many women did not even recognize several key symptoms. This combination has led to dangerous consequences.

2 Feb 2011

New 2010 Dietary Guidelines for Americans addresses unhealthy public

With a majority of the country's adults either overweight or obese, the new 2010 Dietary Guidelines for Americans are the first to address an unhealthy public, making their recommendations especially urgent for consumers and health professionals alike, according to the American Dietetic Association.

2 Feb 2011

Four new fact sheets address impact of combat injury on intimacy

The impact of combat injury on intimacy is an important and often neglected aspect of healthcare communication. Four new fact sheets addressing the impact of the injuries of war, both physical and psychological, on intimacy have just been released for healthcare providers and affected military families.

2 Feb 2011

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Harbor BioSciences, a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced publication of newly discovered anti-inflammatory steroids naturally present in humans.

2 Feb 2011

Nitrate boosts efficiency of mitochondria

The spinach-eating cartoon character Popeye has much to teach us, new research from the Swedish medical university Karolinska Institutet shows. The muscles' cellular power plants - the mitochondria - are boosted by nitrate, a substance found in abundance in vegetables such as lettuce, spinach and beetroot.

2 Feb 2011

New research: Antioxidants in pecans may prevent development of various diseases

A new research study from Loma Linda University demonstrates that naturally occurring antioxidants in pecans may help contribute to heart health and disease prevention; the results are published in the January 2011 issue of The Journal of Nutrition.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011

Multi-national group of researchers announce launch of International Genomics of Alzheimer's Project

The launch of the International Genomics of Alzheimer's Project (IGAP) - a collaboration formed to discover and map the genes that contribute to Alzheimer's disease - was announced today by a multi-national group of researchers including Drs. Lindsay Farrer and Sudha Seshadri at Boston University School of Medicine (BUSM). The collaborative effort, spanning universities from both sides of the Atlantic, will combine the knowledge, staff and resources of four consortia that work on Alzheimer's disease genetics.

2 Feb 2011

New study to address causes and risk factors of ovarian cancer in African American women

University Hospitals Case Medical Center and Case Western Reserve University School of Medicine are conducting an important new study addressing the lack of knowledge about causes and risk factors for ovarian cancer in African American women. The five-year study is funded by the National Cancer Institute through Case Western Reserve University School of Medicine.

2 Feb 2011

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

Zealand Pharma A/S, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, is pleased to announce that its partner, sanofi-aventis, today announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.

2 Feb 2011

New study reports migraine surgery eliminates headache in nearly 30% of patients

Surgery to "deactivate" migraine headaches produces lasting good results, with nearly 90 percent of patients having at least partial relief at five years' follow-up, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

2 Feb 2011

Medical Condition News

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Innovative diabetes management concept can significantly reduce HbA1c values, improve glycemic control

New study evaluates ideal crown-to-root ratio for successful implant restoration

Cognitive behavioral therapy more effective than antidepressant medications for bulimia nervosa

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Study identifies effects of multiple previous concussions on high school students

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

New national initiative to increase heart attack awareness among women

New 2010 Dietary Guidelines for Americans addresses unhealthy public

Four new fact sheets address impact of combat injury on intimacy

Harbor BioSciences announces publication of newly discovered anti-inflammatory steroids

Nitrate boosts efficiency of mitochondria

New research: Antioxidants in pecans may prevent development of various diseases

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Multi-national group of researchers announce launch of International Genomics of Alzheimer's Project

New study to address causes and risk factors of ovarian cancer in African American women

Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes

New study reports migraine surgery eliminates headache in nearly 30% of patients

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News